1-5 of 5
Seiichi Shimizu, MD PhD
Close
Sort by
Journal Articles

Targeting Complete Response with Upfront Bortezomib Followed By Autologous Transplantation and Consolidation Therapy for Untreated Multiple Myeloma (TUBA study)

Hideki Nakasone, MD/PhD, Kiriko Terasako-Saito, Teiichi Hirano, MD, Atsushi Wake, MD PhD, Seiichi Shimizu, MD PhD, Etsuko Yamazaki, MD PhD, Kouhei Akazawa, Kensuke Usuki, MD PhD, Shigeru Chiba, MD, PhD, Koichiro Minauchi, MD, Etsuo Miyaoka, Shuichi Ota, MD, Shuichi Taniguchi, MD PhD, Yoshinobu Kanda, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3463.
https://doi.org/10.1182/blood.V128.22.3463.3463
Published: 2016
Journal Articles

Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR 4.5 ) : First Report from N-Road, a Phase II Study in Japan

Kaichi Nishiwaki, MD PhD, Kei-Ji Sugimoto, MD PhD, Shigehisa Tamaki, MD PhD, Junichi Hisatake, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Atsushi Shinagawa, MD PhD, Takeaki Sugawara, MD PhD, Satoru Hara, MD PhD, Kazuhisa Fujikawa, MD PhD, Seiichi Shimizu, MD PhD, Yujiri Toshiaki, MD PhD, Arinobu Tojo, MD PhD, Hisashi Wakita, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1925.
https://doi.org/10.1182/blood.V128.22.1925.1925
Published: 2016
Journal Articles

Impact of Ph+ Stem Cell Burden on Clinical Findings and Molecular Responses to First-Line Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia: The Results from the Interim Analysis of N-Road, Multi-Center a Phase II Study

Mayuko Tsuda, MD, Kaichi Nishiwaki, MD PhD, Kei-ji Sugimoto, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Seiichi Shimizu, MD PhD, Toshiaki Yujiri, MD PhD, Hisashi Wakita, MD PhD, Arinobu Tojo, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3159.
https://doi.org/10.1182/blood.V124.21.3159.3159
Published: 2014
Journal Articles

Somatic G17V Rhoa Mutation Specifies Angioimmunoblastic T-Cell Lymphoma

Mamiko Sakata-Yanagimoto, MD, PhD, Terukazu Enami, MD, Kenichi Yoshida, MD, Yuichi Shiraishi, PhD, Ryohei Ishii, Yasuyuki Miyake, Hideharu Muto, MD, PhD, Naoko Tsuyama, MD, Yusuke Okuno, MD, PhD, Seiji Sakata, MD, Yuhei Kamada, MD, Rie Nakamoto-Matsubara, MD, Tran Nguyen, MD, Koji Izutsu, MD, PhD, Yasunori Ohta, MD, Junichi Furuta, MD, PhD, Seiichi Shimizu, MD, PhD, Takuya Komeno, MD, PhD, Yuji Sato, MD, Takayoshi Ito, MD, Masayuki Noguchi, MD, PhD, Emiko Noguchi, MD, PhD, Masashi Sanada, MD, Kenichi Chiba, BA, Hiroko Tanaka, BA, Kazumi Suzukawa, MD, PhD, Toru Nanmoku, PhD, Yuichi Hasegawa, MD, PhD, Osamu Nureki, Satoru Miyano, PhD, Naoya Nakamura, M.D., Ph.D., Kengo Takeuchi, MD, PhD, Seishi Ogawa, MD, PhD, Shigeru Chiba, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 815.
https://doi.org/10.1182/blood.V122.21.815.815
Published: 2013
Journal Articles

Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.

Chikashi Yoshida, MD, PhD, Takuya Komeno, MD, MPH, PhD, Mitsuo Hori, MD, PhD, Tomofumi Kimura, MD, PhD, Masami Fujii, MD, PhD, Yasushi Okoshi, MD, PhD, Kazumi Suzukawa, MD, PhD, Shigeru Chiba, MD, PhD, Yuichi Hasegawa, MD, PhD, Harumi Yamamoto Mukai, MD, PhD, Takayoshi Ito, MD, PhD, Seiichi Shimizu, MD, PhD, Masaharu Kamoshita, MD, PhD, Daisuke Kudo, MD, Atsushi Shinagawa, MD, PhD, Norio Chikatsu, MD, PhD, Yuriko Monma, MD, Norimichi Watanabe, MD, PhD, Hiroshi Kojima, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1112.
https://doi.org/10.1182/blood.V114.22.1112.1112
Published: 2009